{
  "symbol": "LLY",
  "year": 2024,
  "Period": "Y2024",
  "report_type": "K10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.1628,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.211
  },
  "top_positive": [
    {
      "sent": "80 Fair Value of Risk-Management Instruments The following table summarizes certain fair value information at December\u00a031, 2023 and 2022 for risk-management assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level\u00a01) Significant Other Observable Inputs (Level\u00a02) Significant Unobservable Inputs (Level 3) Fair Value December 31, 2023 Risk-management instruments Interest rate contracts designated as fair value hedges: Other current liabilities $ ( 2.4 ) $ \u2014 $ ( 2.4 ) $ \u2014 $ ( 2.4 ) Other noncurrent liabilities ( 100.3 ) \u2014 ( 100.3 ) \u2014 ( 100.3 ) Interest rate contracts designated as cash flow hedges: Other noncurrent assets 291.2 \u2014 291.2 \u2014 291.2 Cross-currency interest rate contracts designated as net investment hedges: Other current liabilities ( 28.4 ) \u2014 ( 28.4 ) \u2014 ( 28.4 ) Other noncurrent liabilities ( 3.5 ) \u2014 ( 3.5 ) \u2014 ( 3.5 ) Cross-currency interest rate contracts designated as cash flow hedges: Other receivables 113.8 \u2014 113.8 \u2014 113.8 Other noncurrent assets 63.1 \u2014 63.1 \u2014 63.1 Foreign exchange contracts designated as hedging instruments: Other current liabilities ( 115.8 ) \u2014 ( 115.8 ) \u2014 ( 115.8 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 129.6 \u2014 129.6 \u2014 129.6 Other current liabilities ( 55.9 ) \u2014 ( 55.9 ) \u2014 ( 55.9 ) Contingent consideration liabilities: Other current liabilities ( 39.5 ) \u2014 \u2014 ( 39.5 ) ( 39.5 ) Other noncurrent liabilities ( 64.4 ) \u2014 \u2014 ( 64.4 ) ( 64.4 ) 81 Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level\u00a01) Significant Other Observable Inputs (Level\u00a02) Significant Unobservable Inputs (Level 3) Fair Value December 31, 2022 Risk-management instruments Interest rate contracts designated as fair value hedges: Other noncurrent liabilities $ ( 134.3 ) $ \u2014 $ ( 134.3 ) $ \u2014 $ ( 134.3 ) Interest rate contracts designated as cash flow hedges: Other receivables 162.9 \u2014 162.9 \u2014 162.9 Other noncurrent assets 246.0 \u2014 246.0 \u2014 246.0 Cross-currency interest rate contracts designated as net investment hedges: Other receivables 67.6 \u2014 67.6 \u2014 67.6 Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 53.1 \u2014 53.1 \u2014 53.1 Foreign exchanges contracts designated as hedging instruments: Other current liabilities ( 38.3 ) \u2014 ( 38.3 ) \u2014 ( 38.3 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 26.6 \u2014 26.6 \u2014 26.6 Other current liabilities ( 21.5 ) \u2014 ( 21.5 ) \u2014 ( 21.5 ) Contingent consideration liabilities: Other current liabilities ( 39.5 ) \u2014 \u2014 ( 39.5 ) ( 39.5 ) Other noncurrent liabilities ( 70.6 ) \u2014 \u2014 ( 70.6 ) ( 70.6 ) Risk-management instruments above are disclosed on a gross basis.",
      "score": 0.9948
    },
    {
      "sent": "The fair values of our defined benefit pension plan and retiree health plan assets as of December\u00a031, 2023 by asset category were as follows: Fair Value Measurements Using Asset Class Total Quoted\u00a0Prices in Active Markets\u00a0for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Investments Valued at Net Asset Value (1) Defined Benefit Pension Plans Public equity securities: U.S.",
      "score": 0.9866
    },
    {
      "sent": "59 Consolidated Statements of Shareholders' Equity Equity of Eli Lilly and Company Shareholders ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions, except per-share data, and shares in thousands) Common Stock Additional Paid-in Capital Retained Earnings Employee Benefit Trust Accumulated Other Comprehensive Loss Common Stock in Treasury Noncontrolling Interest Shares Amount Shares Amount Balance at January\u00a01, 2021 957,077 $ 598.2 $ 6,778.5 $ 7,830.2 $ ( 3,013.2 ) $ ( 6,496.4 ) 487 $ ( 55.7 ) $ 183.6 Net income 5,581.7 3.4 Other comprehensive income, net of tax 2,153.3 Cash dividends declared per share: $ 3.53 ( 3,201.7 ) Retirement of treasury shares ( 5,412 ) ( 3.4 ) ( 1,246.6 ) ( 5,412 ) 1,250.0 Purchase of treasury shares 5,412 ( 1,250.0 ) Issuance of stock under employee stock plans, net 2,451 1.5 ( 287.9 ) ( 24 ) 3.0 Stock-based compensation 342.8 Other ( 5.1 ) ( 11.4 ) Balance at December\u00a031, 2021 954,116 596.3 6,833.4 8,958.5 ( 3,013.2 ) ( 4,343.1 ) 463 ( 52.7 ) 175.6 Net income (loss) 6,244.8 ( 20.9 ) Other comprehensive income, net of tax 498.5 Cash dividends declared per share: $ 4.07 ( 3,667.5 ) Retirement of treasury shares ( 5,607 ) ( 3.5 ) ( 1,496.5 ) ( 5,607 ) 1,500.0 Purchase of treasury shares 5,607 ( 1,500.0 ) Issuance of stock under employee stock plans, net 2,123 1.3 ( 283\nments of cash flows and are now included in purchases of IPR&D in cash flows from investing activities.",
      "score": 0.986
    }
  ],
  "top_negative": [
    {
      "sent": "The failure, inadequacy, or breach of our IT systems or business processes, the compromise, disruption, degradation, manipulation, loss, theft, exfiltration, destruction, or unauthorized access to, disclosure or use of, confidential information, or the unauthorized access to, disruption of, or interference with our products and services that rely on IT systems or business processes, could impair our ability to secure and maintain intellectual property rights; result in a product manufacturing interruption or failure, or in the interruption or failure of products or services that rely on IT systems or business processes; damage our operations, patient and other relationships, or reputation; undermine integration activities or otherwise delay or prevent the launch of acquired products; result in unfavorable clinical trial results by virtue of incorrect or unreliable data; expose us to ransom payment, other demands, or paralyze our operations; give rise to legal liability and regulatory action under data protection and privacy laws; require disclosure to government authorities and/or regulators; expose us to civil and criminal investigations; and/or cause us to lose trade secrets or other competitive advantages, which effects could endure for a long period of time.",
      "score": -0.9866
    },
    {
      "sent": "The failure, inadequacy, or breach of our IT systems or business processes, the compromise, disruption, degradation, manipulation, loss, theft, exfiltration, destruction, or unauthorized access to, disclosure or use of, confidential information, or the unauthorized access to, disruption of, or interference with our products and services that rely on IT systems or business processes, could impair our ability to secure and maintain intellectual property rights; result in a product manufacturing interruption or failure, or in the interruption or failure of products or services that rely on IT systems or business processes; damage our operations, patient and other relationships, or reputation; undermine integration activities or otherwise delay or prevent the launch of acquired products; result in unfavorable clinical trial results by virtue of incorrect or unreliable data; expose us to ransom payment, other demands, or paralyze our operations; give rise to legal liability and regulatory action under data protection and privacy laws; require disclosure to government authorities and/or regulators; expose us to civil and criminal investigations; and/or cause us to lose trade secrets or other competitive advantages, which effects could endure for a long period of time.",
      "score": -0.9866
    },
    {
      "sent": "To date, system inadequacies, inadequate controls or procedures, operating failures, unauthorized access, service interruptions or failures, security breaches, malicious intrusions, theft, exfiltration, ransomware, cyber-attacks, and the compromise, disruption, degradation, manipulation, loss, theft, exfiltration, destruction, or unauthorized disclosure or use of confidential information, or the unauthorized access to, disruption of, interference with, or attack of, our IT systems, products and services have not had a material impact on our business strategy, results of operations or financial condition.",
      "score": -0.9825
    }
  ],
  "forward_snippets": [
    "The following include some but not all of the factors that could cause actual results or events to differ from those anticipated: \u2022 the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; \u2022 the impact and uncertain outcome of acquisitions and business development transactions and related costs; \u2022 intense competition affecting our products, pipeline or industry; \u2022 market uptake of launched products and indications; \u2022 continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto; \u2022 safety or efficacy concerns associated with our products; \u2022 dependence on relatively few products or product classes for a significant percentage of our total revenue and an increasingly consolidated supply chain; \u2022 the expiration of intellectual property protection for certain of our products and competition from generic and biosimilar products, and risks from the proliferation of counterfeit or illegally compounded products; \u2022 our ability to protect and enforce patents and other intellectual property and changes in patent law or regulations related to data package exclusivity; \u2022 information technology system inadequacies, inadequate controls or procedures, security breaches, or operating failures; \u2022 unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data and violations of data protection laws or regulations; \u2022 issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities; \u2022 reliance on third-party relationships and outsourcing arrangements; \u2022 the use of artificial intelligence or other emerging technologies in various facets of our operations may exacerbate competitive, regulatory, litigation, cybersecurity and other risks; \u2022 the impact of global macroeconomic conditions, including uneven economic growth or downturns or uncertainty, trade disruptions, international tension, conflicts, regional dependencies, or other costs, uncertainties and risks related to engaging in business globally; \u2022 devaluations in foreign currency exchange rates or changes in interest rates and inflation; \u2022 litigation, investigations, or other similar proceedings involving past, current, or future products or activities; \u2022 changes in tax law and regulation, tax rates, or events that differ from our assumptions related to tax positions; \u2022 regulatory changes and developments; 3 \u2022 regulatory actions regarding our operations and products; \u2022 regulatory compliance problems or government investigations; \u2022 actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations; \u2022 asset impairments and restructuring charges; and \u2022 changes in accounting and reporting standards.",
    "The following include some but not all of the factors that could cause actual results or events to differ from those anticipated: \u2022 the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; \u2022 the impact and uncertain outcome of acquisitions and business development transactions and related costs; \u2022 intense competition affecting our products, pipeline or industry; \u2022 market uptake of launched products and indications; \u2022 continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto; \u2022 safety or efficacy concerns associated with our products; \u2022 dependence on relatively few products or product classes for a significant percentage of our total revenue and an increasingly consolidated supply chain; \u2022 the expiration of intellectual property protection for certain of our products and competition from generic and biosimilar products, and risks from the proliferation of counterfeit or illegally compounded products; \u2022 our ability to protect and enforce patents and other intellectual property and changes in patent law or regulations related to data package exclusivity; \u2022 information technology system inadequacies, inadequate controls or procedures, security breaches, or operating failures; \u2022 unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data and violations of data protection laws or regulations; \u2022 issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities; \u2022 reliance on third-party relationships and outsourcing arrangements; \u2022 the use of artificial intelligence or other emerging technologies in various facets of our operations may exacerbate competitive, regulatory, litigation, cybersecurity and other risks; \u2022 the impact of global macroeconomic conditions, including uneven economic growth or downturns or uncertainty, trade disruptions, international tension, conflicts, regional dependencies, or other costs, uncertainties and risks related to engaging in business globally; \u2022 devaluations in foreign currency exchange rates or changes in interest rates and inflation; \u2022 litigation, investigations, or other similar proceedings involving past, current, or future products or activities; \u2022 changes in tax law and regulation, tax rates, or events that differ from our assumptions related to tax positions; \u2022 regulatory changes and developments; 3 \u2022 regulatory actions regarding our operations and products; \u2022 regulatory compliance problems or government investigations; \u2022 actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations; \u2022 asset impairments and restructuring charges; and \u2022 changes in accounting and reporting standards.",
    "We believe our long-term competitive success depends on discovering and developing (either alone or in collaboration with others) or acquiring innovative, cost-effective products that provide improved outcomes for patients and deliver value to payers, and continuously improving the productivity of our operations in a highly competitive environment.",
    "In addition, competition for our biologics, which constitute a substantial portion of our products and pipeline, may be affected by the approval of follow-on biologics, also known as biosimilars.",
    "In addition, competition for our biologics, which constitute a substantial portion of our products and pipeline, may be affected by the approval of follow-on biologics, also known as biosimilars."
  ]
}